Physician profile
Jacqueline E Gabay
NPI 1245310531
$8,143.16
in general payments reported to CMS, 2019-2025
31 companies · $1,971 in 2025
The $1,971 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $643 · 2021: $1,016 · 2022: $847 · 2023: $728 · 2024: $2,062 · 2025: $1,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,726 · Education: $34.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,725.58 |
| Education | $34.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,294.85 | 2020-2025 | Idose, Idosetr |
| Abbvie INC. | $1,049.57 | 2022-2025 | |
| Allergan, INC. | $995.65 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $795.29 | 2019-2025 | Cequa |
| Alcon Vision LLC | $555.37 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $390.66 | 2023-2025 | Vyzulta, Envista Mx60 Iol, Miebo |
| Harrow Eye, LLC | $341.94 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $311.75 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $265.47 | 2021-2025 | Clearpath, Via360, Streamline |
| Novartis Pharmaceuticals Corporation | $232.14 | 2019-2023 | |
| Emergent Biosolutions INC. | $212.02 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $184.80 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Oyster Point Pharma, INC. | $182.97 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $180.07 | 2021-2024 | |
| Tarsus Pharmaceuticals, INC. | $144.67 | 2024-2025 | Xdemvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $139.29 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Glaxosmithkline, LLC. | $120.69 | 2021 | |
| Shire North American Group INC | $101.95 | 2019 | |
| Dompe US, INC. | $101.95 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $90.50 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $87.01 | 2019-2021 | |
| Ocular Therapeutix, INC. | $78.54 | 2021-2024 | Dextenza |
| Mallinckrodt Hospital Products INC. | $62.06 | 2020-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.45 | 2019-2021 | |
| Notal Vision, INC. | $47.72 | 2021 | |
| Amgen INC. | $27.69 | 2024 | Tepezza |
| Alimera Sciences, INC. | $21.11 | 2024 | Iluvien, Yutiq |
| Ivantis, INC | $20.45 | 2019 | |
| Apellis Pharmaceuticals, INC. | $20.04 | 2024 | Syfovre |
| Travere Therapeutics, INC. | $17.05 | 2021 | |
| Rayner Intraocular Lenses Limited | $16.44 | 2025 | Omidria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Gabay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.